GPRC6A and prostate cancer: Overall, these findings are consistent with prior in vitro studies showing that activation of GPRC6A in human PC-3 and 22Rv1 cells results in ERK phosphorylation, cell proliferation, and chemotaxis [12]; that knockdown of GPRC6A by siRNA inhibited PC-3 prostate cancer cell migration and invasion, and that overexpression of GPRC6A promoted prostate cancer epithelial-mesenchymal transition [20].